PTX.AX - Prescient Therapeutics Limited

ASX - ASX Delayed price. Currency in AUD

Prescient Therapeutics Limited

100 Albert Road
Level 4
South Melbourne, VIC 3205
61 3 9692 7222

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Yatomi-Clarke Steven LeeMD, CEO & Director404.96kN/AN/A
Prof. Said M. SebtiChief Scientific Officer161.79kN/AN/A
Dr. Terrence G. ChewChief Medical Officer158.77kN/A1947
Ms. Melanie Jaye Leydin C.A., B.Bus, CACompany Sec.102kN/A1973
Dr. Claudia Gregorio-KingVP of OperationsN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for negative breast cancer, as well as Phase IB clinical trial in relapsed and refractory ovarian cancer and acute leukemia; and PTX-100, a treatment that has completed Phase I clinical trial for solid tumors. It has a collaboration agreement with Carina Biotech to develop next generation cellular therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited is based in South Melbourne, Australia.

Corporate governance

Prescient Therapeutics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.